Jacob Levy
Family · Brooklyn, NYNPI 1710351515
Payments from drug & device makers
Across 232 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$667
- Lilly USA, LLC$470
- Amgen$468
- GSK$342
- AstraZeneca$332
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,35198%
- Education$1062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 50 | $1,067 |
| AbbVie | 28 | $667 |
| Lilly USA, LLC | 21 | $470 |
| Amgen | 13 | $468 |
| GSK | 17 | $342 |
| AstraZeneca | 16 | $332 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $319 |
| Novo Nordisk | 9 | $311 |
| Merck | 12 | $267 |
| Amarin Pharma, Inc. | 9 | $184 |
| Astellas Pharma US Inc | 5 | $183 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| Kowa Pharmaceuticals America, Inc. | 6 | $113 |
| Pfizer | 5 | $99 |
| Renalytix AI, Inc. | 4 | $73 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Abbott | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Orexo US, Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Valinor Pharma, LLC | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Bayer | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Biogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$272
- Austedo XR$125
- Ozempic$125
- CAPLYTA$102
How this compares
$5,457 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metformin Hcl | 146 | $87,377 |
| OzempicSemaglutide | 59 | $59,555 |
| JanuviaSitagliptin Phosphate | 51 | $50,283 |
| MounjaroTirzepatide | 37 | $47,066 |
| EliquisApixaban | 50 | $44,802 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $44,020 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $40,726 |
| VascepaIcosapent Ethyl | 65 | $34,479 |
| XareltoRivaroxaban | 24 | $26,094 |
| AirsupraAlbuterol Sulfate/Budesonide | 36 | $23,826 |
| Abilify MaintenaAripiprazole | 11 | $22,945 |
| Diclofenac Sodium | 38 | $19,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,328 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $18,447 |
| LinzessLinaclotide | 25 | $17,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $267 | $64,35267 claims |
| Lilly USA, LLCMounjaro, Trulicity | $470 | $61,56148 claims |
| Novo NordiskOzempic | $311 | $59,55559 claims |
| AstraZenecaAirsupra, Breztri Aerosphere, Symbicort | $332 | $46,82466 claims |
| PfizerEliquis | $99 | $44,80250 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $342 | $30,01158 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $136 | $22,94511 claims |
| AbbVieLinzess | $667 | $17,13725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.